AKT1 and major depressive disorder: Base on the network pharmacology analysis and molecular docking, we found PI3K-Akt pathway is one of the targets of ASD to against the disorders involving impaired neurogenesis, such as Alzheimer’s disease, major depressive disorder and anxiety disorder.